Zhende Medical Co., Ltd. (SHA:603301)
China · Delayed Price · Currency is CNY 94.76
+1.25 (1.34%)
May 8, 2026, 3:00 PM CST
Zhende Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,338 | 4,330 | 4,247 | 4,105 | 6,131 | 4,907 |
Other Revenue | - | - | 16.67 | 21.6 | 6.47 | 184.42 |
| 4,338 | 4,330 | 4,264 | 4,127 | 6,138 | 5,092 | |
Revenue Growth (YoY) | 1.09% | 1.54% | 3.32% | -32.76% | 20.54% | -51.04% |
Cost of Revenue | 2,864 | 2,861 | 2,850 | 2,850 | 4,063 | 3,353 |
Gross Profit | 1,475 | 1,469 | 1,414 | 1,277 | 2,075 | 1,738 |
Selling, General & Admin | 933.94 | 926 | 890.18 | 894.44 | 984.23 | 808.32 |
Research & Development | 139.55 | 142.43 | 135.49 | 138.95 | 227 | 153.14 |
Other Operating Expenses | 11.27 | 11.9 | 2.92 | 8.15 | 41.8 | 48.33 |
Operating Expenses | 1,085 | 1,080 | 1,039 | 1,043 | 1,262 | 1,011 |
Operating Income | 389.86 | 388.3 | 375.05 | 233.3 | 812.89 | 727.2 |
Interest Expense | - | - | -28.73 | -28.93 | -33.54 | -25.07 |
Interest & Investment Income | 13.16 | 10.46 | 35.92 | 46.76 | 10.61 | 52.4 |
Currency Exchange Gain (Loss) | - | - | 24.3 | 11.76 | 21.89 | -15.69 |
Other Non Operating Income (Expenses) | -50.34 | -41.27 | -2.87 | -1.98 | -1.03 | -2.07 |
EBT Excluding Unusual Items | 352.69 | 357.49 | 403.68 | 260.9 | 810.81 | 736.77 |
Impairment of Goodwill | - | - | - | -2.29 | -3.91 | - |
Gain (Loss) on Sale of Investments | 9.37 | 0.63 | -12.25 | -21.06 | -71.06 | -2.7 |
Gain (Loss) on Sale of Assets | 0.26 | 0.64 | 93.43 | -15.96 | -13.53 | -0.61 |
Asset Writedown | -33.25 | -33.93 | -9.09 | -52.02 | -4.97 | -3.31 |
Other Unusual Items | - | - | -0.31 | 49.34 | 84.38 | 89.81 |
Pretax Income | 329.07 | 324.83 | 475.46 | 218.89 | 801.72 | 819.95 |
Income Tax Expense | 56.81 | 57.73 | 78.25 | 5.49 | 99.96 | 99 |
Earnings From Continuing Operations | 272.25 | 267.1 | 397.21 | 213.4 | 701.76 | 720.95 |
Minority Interest in Earnings | -8.23 | -6.28 | -12.04 | -15 | -21.88 | -125.08 |
Net Income | 264.02 | 260.82 | 385.17 | 198.4 | 679.88 | 595.86 |
Net Income to Common | 264.02 | 260.82 | 385.17 | 198.4 | 679.88 | 595.86 |
Net Income Growth | -27.27% | -32.29% | 94.14% | -70.82% | 14.10% | -76.63% |
Shares Outstanding (Basic) | 264 | 263 | 266 | 268 | 237 | 226 |
Shares Outstanding (Diluted) | 264 | 263 | 266 | 268 | 237 | 227 |
Shares Change (YoY) | -1.29% | -0.82% | -0.92% | 13.18% | 4.56% | 11.08% |
EPS (Basic) | 1.00 | 0.99 | 1.45 | 0.74 | 2.87 | 2.64 |
EPS (Diluted) | 1.00 | 0.99 | 1.45 | 0.74 | 2.87 | 2.63 |
EPS Growth | -26.32% | -31.72% | 95.95% | -74.22% | 9.13% | -78.96% |
Free Cash Flow | 140.68 | -11.73 | -308.55 | -147.13 | 491.92 | 122.16 |
Free Cash Flow Per Share | 0.53 | -0.04 | -1.16 | -0.55 | 2.08 | 0.54 |
Dividend Per Share | - | - | 0.650 | 1.250 | - | 0.600 |
Dividend Growth | - | - | -48.00% | - | - | -73.91% |
Gross Margin | 33.99% | 33.92% | 33.16% | 30.93% | 33.80% | 34.14% |
Operating Margin | 8.99% | 8.97% | 8.80% | 5.65% | 13.24% | 14.28% |
Profit Margin | 6.09% | 6.02% | 9.03% | 4.81% | 11.08% | 11.70% |
Free Cash Flow Margin | 3.24% | -0.27% | -7.24% | -3.56% | 8.02% | 2.40% |
EBITDA | 702.26 | 685.68 | 612.37 | 476.27 | 998.26 | 858.7 |
EBITDA Margin | 16.19% | 15.84% | 14.36% | 11.54% | 16.27% | 16.86% |
D&A For EBITDA | 312.39 | 297.38 | 237.32 | 242.97 | 185.38 | 131.51 |
EBIT | 389.86 | 388.3 | 375.05 | 233.3 | 812.89 | 727.2 |
EBIT Margin | 8.99% | 8.97% | 8.80% | 5.65% | 13.24% | 14.28% |
Effective Tax Rate | 17.27% | 17.77% | 16.46% | 2.51% | 12.47% | 12.07% |
Revenue as Reported | - | - | 4,264 | 4,127 | 6,138 | 5,092 |
Advertising Expenses | - | - | 42.83 | 38.17 | 39.94 | 20.1 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.